Regular boost for high fibre research
25 July, 2007 by Staff WritersCSIRO and universities come together to research new grain varieties with higher fibre.
Microbicide well tolerated, even by men
24 July, 2007 by Staff WritersStarpharma's anti-HIV and herpes microbicide is well tolerated by men, the company told the IAS conference today.
Bioscience heading to Honkers
23 July, 2007 by External Press Release AuthorBioscience companies are invited to attend a trade mission to Hong Kong.
737 boosts leukaemia drugs
19 July, 2007 by Staff WritersStudy finds Abbott Laboratories' ABT-737 increases therapy effectiveness.
Biota starts RSV trial
17 July, 2007 by Staff WritersBiota and partner MedImmune begin antiviral trial for respiratory virus.
Starpharma's VivaGel on trial
10 July, 2007 by Kate McDonaldNIH-funded trial of Starpharma's VivaGel microbicide under way in US.
Monoclonal antibodies for Monash
05 July, 2007 by Staff WritersMonash University and Tecan to build monoclonal antibody production facility.
Cheers to beer and all things yeasty
02 July, 2007 by Kate McDonald500 international yeast biologists have descended on Melbourne.
Commercialisation bootcamp in Brisbane
28 June, 2007 by Staff Writers'Bootcamp' for Brisbane researchers interested in learning more about the business of commercialisation.
Giaconda begins hep C trial
27 June, 2007 by Staff WritersCombination therapy trial for refractory hep C begins.
Bone repair trial yields growth
22 June, 2007 by Kate McDonaldMesoblast announces strong interim results in fracture repair trial.
VitroGro gets topical
21 June, 2007 by Kate McDonaldBiologic classification to fast-track VitroGro development.
Southbank TAFE sets up biotech course
20 June, 2007 by Kate McDonaldNew course for science grads looking for hands-on experience.
Polyoleosins: close sesame
18 June, 2007 by Graeme O'NeillNZ researchers have developed a potential biological solution to prevent lipids being transformed into trans fats.
GSK ramps up cancer pipeline
18 June, 2007 by Kate McDonaldGSK to launch up to five major cancer drugs in next three years.
